Genetically engineered mouse models and human osteosarcoma

Alvin Jm Ng; Anthony J Mutsaers; Emma K Baker; Carl R Walkley

doi:10.1186/2045-3329-2-19

Genetically engineered mouse models and human osteosarcoma

Clin Sarcoma Res. 2012 Oct 4;2(1):19. doi: 10.1186/2045-3329-2-19.

Authors

Alvin Jm Ng^#^{1

2}, Anthony J Mutsaers^#^{1

2

3}, Emma K Baker^{1

2}, Carl R Walkley^{1

2}

Affiliations

¹ St Vincent's Institute of Medical Research, 9 Princes Street, Fitzroy, VIC, 3065, Australia.
² Department of Medicine, University of Melbourne, St. Vincent's Hospital, Fitzroy, VIC, 3065, Australia.
³ Ontario Veterinary College, University of Guelph, 50 Stone Road, Guelph, ON, N1G 2W1, Canada.

^# Contributed equally.

Abstract

Osteosarcoma is the most common form of bone cancer. Pivotal insight into the genes involved in human osteosarcoma has been provided by the study of rare familial cancer predisposition syndromes. Three kindreds stand out as predisposing to the development of osteosarcoma: Li-Fraumeni syndrome, familial retinoblastoma and RecQ helicase disorders, which include Rothmund-Thomson Syndrome in particular. These disorders have highlighted the important roles of P53 and RB respectively, in the development of osteosarcoma. The association of OS with RECQL4 mutations is apparent but the relevance of this to OS is uncertain as mutations in RECQL4 are not found in sporadic OS. Application of the knowledge or mutations of P53 and RB in familial and sporadic OS has enabled the development of tractable, highly penetrant murine models of OS. These models share many of the cardinal features associated with human osteosarcoma including, importantly, a high incidence of spontaneous metastasis. The recent development of these models has been a significant advance for efforts to improve our understanding of the genetics of human OS and, more critically, to provide a high-throughput genetically modifiable platform for preclinical evaluation of new therapeutics.